There is a Role for Currently Available Biomarkers: Genomics in the Risk Stratification of Prostate Cancer

Timothy C. Brand, MD, FACS, argues that biomarkers and genomics have a role in the clinical decision-making process for individual patients with low- and favorable intermediate-risk prostate cancer. He also reviews the literature validating the risk stratification utility of recommended biomarkers.

Read More